May 20, 2026 07:15AM
May 16, 2026 08:00AM
Feb 27, 2026 06:20AM
Jan 21, 2026 11:45AM
Jan 13, 2026 12:19PM
Nov 7, 2025 08:50AM
Nov 7, 2025 08:42AM Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
Sep 19, 2025 07:59AM
Jul 24, 2025 01:41PM
Jun 20, 2025 06:19AM
May 6, 2025 01:30AM
Apr 24, 2025 02:14AM
Sep 23, 2024 07:13AM
Jul 26, 2024 06:46AM Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Jun 10, 2024 04:54PM
Jun 7, 2024 01:00AM
May 2, 2024 01:30AM
Apr 24, 2024 01:00AM
Feb 13, 2024 04:08PM
Dec 7, 2023 01:00AM
Nov 13, 2023 07:00AM Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Oct 23, 2023 01:00AM
Sep 4, 2023 01:00AM
Sep 1, 2023 01:00AM
Aug 16, 2023 03:32PM
Jul 21, 2023 08:52AM
Jul 21, 2023 07:52AM
Jul 19, 2023 12:42PM Ipsen announces European Commission decision on palovarotene for the treatment of FOP
Jun 28, 2023 08:00PM
Jun 14, 2023 04:35PM
Jun 14, 2023 02:21PM
Jun 13, 2023 01:10PM
Jun 12, 2023 01:00AM
May 26, 2023 08:20AM
Apr 27, 2023 01:00AM Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
Apr 24, 2023 02:00AM
Mar 16, 2023 02:02PM
Mar 2, 2023 02:13PM
Feb 15, 2023 01:00AM
Feb 13, 2023 05:00PM
Feb 9, 2023 01:00AM
Jan 27, 2023 01:00AM Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
Jan 20, 2023 10:00AM
Jan 9, 2023 01:00AM
Dec 23, 2022 05:00PM
Dec 8, 2022 04:05PM
Nov 9, 2022 06:57AM
Nov 9, 2022 01:01AM
Oct 27, 2022 12:57AM Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
Oct 25, 2022 10:20AM

1,197,526 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All